Brain tumour chemotherapy now available to even more NHS patients

July 11, 2018, Cancer Research UK
Brain tumour chemotherapy now available to even more NHS patients
Credit: Cancer Research UK

Science can be a painstakingly slow process. It can take years of tweaking, refining and rethinking to get solid, reliable evidence. And when it comes to developing new cancer treatments, the layers of research needed go even deeper.

Not only do scientists need to prove that a potential drug does what it's supposed to – and in a way that makes it better than existing treatments – they also need to be sure it's safe. Since people – and cancers – are so different from one another, this takes a lot of work. That's why it can take 10-20 years for a discovery to complete the journey from lab bench to bedside.

While this is an essential part of developing the treatments of tomorrow, such knowledge may be little consolation for today's patients. So, what can be done to accelerate improvements for people with cancer? Work with the options we already have.

This is an approach many of our researchers are taking, and an announcement today from the National Institute for Health and Care Excellence (NICE) shows how improving treatments isn't necessarily a case of out with the old and in with the new.

Thanks to a trial we supported, people with a type of brain tumour now have a new treatment option. And it's a chemotherapy drug our scientists began developing more than 30 years ago.

"This is a practice-changing trial," says Dr. Sara Erridge, a Cancer Research UK-funded scientist at the University of Edinburgh, who led the UK arm of the international CATNON (BR14) study.

"Temozolomide has now been introduced to be part of the standard of care for this group of patients."

Expanding temozolomide's horizons

The global trial focused on improving treatment for people with a type of brain tumour called a glioma. These start in cells called glia, which play many roles in the brain such as supporting nerve cells. In some gliomas, the tumour cells have genetic mistakes where bits of 2 different chromosomes are missing. This trial was for people whose cells didn't have this genetic scar – known as 'non-codeleted' gliomas.

Prior work had shown that people with non-codeleted gliomas tended to do worse than people whose tumours did have this genetic fault. The researchers wanted to find out whether the chemotherapy drug temozolomide could improve survival for some people who fall in this group.

"In one of my jobs first junior doctor I was involved in caring for patients in the early clinical studies of temozolomide, so I've seen this drug through many generations," Dr. Erridge says.

"Temozolomide is used as part of the standard of care for fitter people with grade 4 gliomas, the highest grade and most aggressive type of brain tumour. What we've been trying to find out is whether temozolomide improves survival in people who have non-codeleted grade 3 tumours."

Grades are a measure of how fast-growing a tumour is, based on how abnormal the cells look under the microscope. High grade gliomas – grades 3 or 4 – look most different from healthy cells and grow the quickest.

Early signs of success

Taking place across 12 countries in Europe, Australia and Canada, the trial included 750 patients and looked at the benefits of adding temozolomide to radiotherapy – either at the same time or afterwards. While the team is still collecting data from people who were given the drug and radiotherapy together, Dr. Erridge says it became clear early on that temozolomide was helping patients when given after radiotherapy.

"An independent data monitoring committee took a look at the data shortly after we'd finished recruiting, examining the treatment's effectiveness and safety," she says.

"They identified that people who had been given the chemotherapy following radiotherapy had a survival advantage, even at an early analysis of the data. So, they made immediate recommendations that anyone who had received radiotherapy should be given temozolomide."

Late last year, these early results were published in The Lancet. Compared with radiotherapy alone, adding in after radiotherapy increased the number of patients who were alive 5 years on from just over 4 in 10 (44%) to almost 6 in 10 (56%).

"The great thing is that this isn't an expensive treatment. Temozolomide is a generic drug, so it's easy to implement into the NHS at a minimal cost," Dr. Erridge says.

"It's a healthcare development that the NHS can actually afford; it's realistic."

Keeping care in focus

NICE's decision to update its guidelines following this trial will no doubt be welcome news for those who could benefit. And while boosting survival is of course the goal for these hard-to-treat cancers, Dr. Erridge wants to make sure that quality of life isn't sacrificed to get there.

"The focus tends to be on helping people live longer, but brain tumours affect people in so many other ways – their mental capabilities, mobility and even who they are; their identity," she says.

"For many patients, their priorities tend to be about care and making their quality of life better. That presents us doctors with a dilemma, as we want to improve survival but often the quality of that extended life is quite poor. How can we make that extra time as good as it can be?"

As part of our inaugural Brain Tumour Awards, we're calling on researchers to find ways to do just that. By learning more about the biology of different brain tumours, we hope to identify those that can be treated just as effectively with gentler treatments, thus reducing the risk of long-term side effects.

This is just one of many new efforts we're making to help transform the outlook for people with . And even if the progress we make is incremental, research like the CATNON trial shows that small steps can make a big difference.

Explore further: Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour

More information: Martin J. van den Bent et al. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial, Journal of Clinical Oncology (2006). DOI: 10.1200/JCO.2005.04.6078

Related Stories

Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour

June 3, 2016
GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent.

Genetic biomarker linked to improved survival for patients with certain brain tumors

June 28, 2018
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative ...

Scientists exploit leaks in blood brain barrier to treat glioblastoma

November 6, 2017
An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma, suggest results presented at the National Cancer Research Institute's (NCRI) Cancer ...

Revamped drug may overcome resistance in brain tumours

January 14, 2015
Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults, according to research published in Molecular Cancer Therapeutics.

Altitude sickness drug appears to slow progression of glioblastoma

July 9, 2018
A drug used to treat altitude sickness—as well as glaucoma, epilepsy, heart failure and seizures—may also offer significant gains for patients with a fast-growing brain tumor known as glioblastoma, according to a study ...

MGMT promoter methylation associated with improved survival for patients with WHO Grade II Gliomas

July 5, 2018
Further exploration into the endpoints of the NRG Oncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide ...

Recommended for you

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

A molecule for fighting muscular paralysis

November 19, 2018
Myotubular myopathy is a severe genetic disease that leads to muscle paralysis from birth and results in death before two years of age. Although no treatment currently exists, researchers from the University of Geneva (UNIGE), ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.